Leerink Partnrs Has Positive Outlook for Medpace Q3 Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) – Leerink Partnrs boosted their Q3 2025 EPS estimates for shares of Medpace in a research note issued to investors on Tuesday, July 22nd. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $3.64 per share for the quarter, up from their previous estimate of $2.94. The consensus estimate for Medpace’s current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace’s Q4 2025 earnings at $3.71 EPS, FY2025 earnings at $14.11 EPS, FY2026 earnings at $15.78 EPS, FY2027 earnings at $18.22 EPS and FY2028 earnings at $20.93 EPS.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. During the same period in the prior year, the firm earned $2.75 EPS. Medpace’s quarterly revenue was up 14.2% compared to the same quarter last year.

A number of other analysts also recently weighed in on MEDP. Cowen downgraded shares of Medpace from a “buy” rating to a “sell” rating in a report on Wednesday. Barclays raised their price objective on shares of Medpace from $300.00 to $450.00 and gave the stock an “equal weight” rating in a report on Wednesday. Truist Financial raised their price objective on shares of Medpace from $298.00 to $436.00 and gave the stock a “hold” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a report on Wednesday. Finally, William Blair reissued a “market perform” rating on shares of Medpace in a report on Wednesday. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $411.10.

Medpace Trading Down 1.8%

NASDAQ:MEDP opened at $447.49 on Friday. Medpace has a 1 year low of $250.05 and a 1 year high of $501.30. The firm’s fifty day simple moving average is $319.66 and its 200 day simple moving average is $321.05. The firm has a market capitalization of $12.57 billion, a PE ratio of 33.27, a PEG ratio of 2.91 and a beta of 1.47.

Institutional Trading of Medpace

A number of institutional investors have recently made changes to their positions in MEDP. Geneos Wealth Management Inc. raised its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares in the last quarter. Brooklyn Investment Group increased its holdings in shares of Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after purchasing an additional 71 shares during the last quarter. Whittier Trust Co. increased its holdings in shares of Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after purchasing an additional 35 shares during the last quarter. Colonial Trust Co SC increased its holdings in shares of Medpace by 150.0% in the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company’s stock valued at $58,000 after purchasing an additional 105 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Medpace in the first quarter valued at $60,000. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.